Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF et al. Classification of primary progressive aphasia and its variants. Am Acad Neurol. 2011;76.

Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456–77.

PubMed  PubMed Central  Google Scholar 

Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B et al. Criteria for the diagnosis of corticobasal degeneration. Am Acad Neurol. 2013;80.

Hoglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853–64.

PubMed  PubMed Central  Google Scholar 

Irwin DJ, Cairns NJ, Grossman M, McMillan CT, Lee EB, Van Deerlin VM, et al. Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol. 2015;129(4):469–91.

PubMed  Google Scholar 

Mann DMA, Snowden JS. Frontotemporal lobar degeneration: pathogenesis, pathology and pathways to phenotype. Brain Pathol. 2017;27(6):723–36.

CAS  PubMed  PubMed Central  Google Scholar 

Neumann M, Rademakers R, Roeber S, Baker M, Kretzschmar HA, Mackenzie IR. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain. 2009;132(Pt 11):2922–31.

PubMed  PubMed Central  Google Scholar 

Lashley T, Rohrer JD, Mead S, Revesz T. Review: an update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations. Neuropathol Appl Neurobiol. 2015;41(7):858–81.

PubMed  Google Scholar 

Rohrer JD, Guerreiro R, Vandrovcova J, Uphill J, Reiman D, Beck J et al. The heritability and genetics of frontotemporal lobar degeneration. Neurology. 2009;73.

Greaves CV, Rohrer JD. An update on genetic frontotemporal dementia. J Neurol. 2019;266(8):2075–86.

PubMed  PubMed Central  Google Scholar 

Pozzi FE, Aprea V, Giovannelli G, Lattuada F, Crivellaro C, Bertola F, et al. Clinical and neuroimaging characterization of the first frontotemporal dementia family carrying the MAPT p.K298E mutation. Neurogenetics. 2024;25(3):215–23.

CAS  PubMed  PubMed Central  Google Scholar 

Cheng HR, Lin RR, Li HL, Xue YY, Gao PR, Chen DF, et al. Identification and functional characterization of novel variants of MAPT and GRN in Chinese patients with frontotemporal dementia. Neurobiol Aging. 2023;123:233–43.

CAS  PubMed  Google Scholar 

Neumann M, Lee EB, Mackenzie IR. Frontotemporal lobar degeneration TDP-43-immunoreactive pathological subtypes: clinical and mechanistic significance. Adv Exp Med Biol. 2021;1281:201–17.

CAS  PubMed  PubMed Central  Google Scholar 

Del Campo M, Zetterberg H, Gandy S, Onyike CU, Oliveira F, Udeh-Momoh C, et al. New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia. Alzheimers Dement. 2022;18(11):2292–307.

PubMed  Google Scholar 

Hutchinson AD, Mathias JL. Neuropsychological deficits in frontotemporal dementia and alzheimer’s disease: a meta-analytic review. J Neurol Neurosurg Psychiatry. 2007;78(9):917–28.

CAS  PubMed  PubMed Central  Google Scholar 

Naasan G, Rabinovici GD, Ghosh P, Elofson JD, Miller BL, Coppola G, et al. Amyloid in dementia associated with Familial FTLD: not an innocent bystander. Neurocase. 2016;22(1):76–83.

PubMed  Google Scholar 

Irwin DJ, Trojanowski JQ, Grossman M. Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from alzheimer’s disease. Front Aging Neurosci. 2013;5:6.

CAS  PubMed  PubMed Central  Google Scholar 

Ashton NJ, Janelidze S, Al Khleifat A, Leuzy A, van der Ende EL, Karikari TK, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun. 2021;12(1):3400.

CAS  PubMed  PubMed Central  Google Scholar 

Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE, and the, NFLG et al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol. 2019;76(9):10354–8.

Ducharme S, Dols A, Laforce R, Devenney E, Kumfor F, van den Stock J, et al. Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain. 2020;143(6):1632–50.

PubMed  PubMed Central  Google Scholar 

Gendron TF, Heckman MG, White LJ, Veire AM, Pedraza O, Burch AR, et al. Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders. Cell Rep Med. 2022;3(4):100607.

CAS  PubMed  PubMed Central  Google Scholar 

Meeter LHH, Vijverberg EG, Del Campo M, Rozemuller AJM, Donker Kaat L, de Jong FJ, et al. Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. Neurology. 2018;90(14):e1231–9.

CAS  PubMed  PubMed Central  Google Scholar 

Pijnenburg YA, Verwey NA, van der Flier WM, Scheltens P, Teunissen CE. Discriminative and prognostic potential of cerebrospinal fluid phosphotau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimers Dement (Amst). 2015;1(4):505–12.

PubMed  Google Scholar 

Cousins KAQ, Shaw LM, Chen-Plotkin A, Wolk DA, Van Deerlin VM, Lee EB, et al. Distinguishing frontotemporal lobar degeneration Tau from TDP-43 using plasma biomarkers. JAMA Neurol. 2022;79(11):1155–64.

PubMed  PubMed Central  Google Scholar 

Desmarais P, Rohrer JD, Nguyen QD, Herrmann N, Stuss DT, Lang AE, et al. Therapeutic trial design for frontotemporal dementia and related disorders. J Neurol Neurosurg Psychiatry. 2019;90(4):412–23.

PubMed  Google Scholar 

Higginbotham L, Ping L, Dammer EB, Duong DM, Zhou M, Gearing M, et al. Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic alzheimer’s disease. Sci Adv. 2020;6:43.

Google Scholar 

Bader JM, Geyer PE, Muller JB, Strauss MT, Koch M, Leypoldt F, et al. Proteome profiling in cerebrospinal fluid reveals novel biomarkers of alzheimer’s disease. Mol Syst Biol. 2020;16(6):e9356.

CAS  PubMed  PubMed Central  Google Scholar 

Dammer EB, Ping L, Duong DM, Modeste ES, Seyfried NT, Lah JJ, et al. Multi-platform proteomic analysis of alzheimer’s disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome. Alzheimers Res Ther. 2022;14(1):174.

CAS  PubMed  PubMed Central  Google Scholar 

Del Campo M, Peeters CFW, Johnson ECB, Vermunt L, Hok-A-Hin YS, van Nee M, et al. CSF proteome profiling across the alzheimer’s disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels. Nat Aging. 2022;2(11):1040–53.

PubMed  PubMed Central  Google Scholar 

Teunissen CE, Elias N, Koel-Simmelink MJ, Durieux-Lu S, Malekzadeh A, Pham TV, et al. Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. Alzheimers Dement (Amst). 2016;2:86–94.

PubMed  Google Scholar 

van der Ende EL, Meeter LH, Stingl C, van Rooij JGJ, Stoop MP, Nijholt DAT, et al. Novel CSF biomarkers in genetic frontotemporal dementia identified by proteomics. Ann Clin Transl Neurol. 2019;6(4):698–707.

PubMed  PubMed Central  Google Scholar 

Del Campo M, Galimberti D, Elias N, Boonkamp L, Pijnenburg YA, van Swieten JC, et al. Novel CSF biomarkers to discriminate FTLD and its pathological subtypes. Ann Clin Transl Neurol. 2018;5(10):1163–75.

PubMed  PubMed Central  Google Scholar 

van der Ende EL, Xiao M, Xu D, Poos JM, Panman JL, Jiskoot LC, et al. Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2020;91(6):612–21.

PubMed  Google Scholar 

Bolsewig K, Hok AHYS, Sepe FN, Boonkamp L, Jacobs D, Bellomo G, et al. A combination of neurofilament light, glial fibrillary acidic protein, and neuronal Pentraxin-2 discriminates between frontotemporal dementia and other dementias. J Alzheimers Dis. 2022;90(1):363–80.

CAS  PubMed  PubMed Central  Google Scholar 

Llorens F, Thune K, Tahir W, Kanata E, Diaz-Lucena D, Xanthopoulos K, et al. YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias. Mol Neurodegener. 2017;12(1):83.

PubMed  PubMed Central  Google Scholar 

Del Campo M, Vermunt L, Peeters CFW, Sieben A, Hok AHYS, Lleo A, et al. CSF proteome profiling reveals biomarkers to discriminate dementia with lewy bodies from alzheimer s disease. Nat Commun. 2023;14(1):5635.

PubMed  PubMed Central  Google Scholar 

van der Flier WM, Scheltens P. Amsterdam dementia cohort: performing research to optimize care. J Alzheimers Dis. 2018;62(3):1091–111.

PubMed  PubMed Central  Google Scholar 

Ingelsson M, Ramasamy K, Russ C, Freeman SH, Orne J, Raju S, et al. Increase in the relative expression of Tau with four microtubule binding repeat regions in frontotemporal Lobar degeneration and progressive supranuclear palsy brains. Acta Neuropathol. 2007;114(5):471–9.

CAS  PubMed  Google Scholar 

Alcolea D, Clarimon J, Carmona-Iragui M, Illan-Gala I, Morenas-Rodriguez E, Barroeta I, et al. The Sant Pau initiative on neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. Alzheimers Dement (N Y). 2019;5:597–609.

PubMed  Google Scholar